Skip to Content

Perioperative Pembrolizumab Shows Significant OS in ResectableNon-Small-Cell Lung Cancer

The results of KEYNOTE 671 reveal that perioperative chemotherapy with pembrolizumab improves overall survival in resectable non-small-cell lung cancer. Jonathan Spicer presents the study and discusses the concerns regarding patient drop-off in neoadjuvant studies and the positive patient dispositions achieved with this approach.

Jonathan Spicer

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top